The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Centrix Pharma Solutions is a UK-based, development-focused CDMO specialising in early-stage drug product development and clinical trial manufacturing for orally delivered small molecules.
 
Built on the heritage of Custom Pharma Services (established in 1979), Centrix was created to support the most critical stages of drug development. guiding innovative biotech companies from concept to clinic with confidence. Our approach is rooted in deep pharmaceutical science, patient-centric design, and proactive risk management, ensuring drug products are designed right from the start.
 
We work as a genuine partner to our clients, combining formulation development, analytical strategy, and GMP clinical manufacturing within an integrated, agile model. By aligning product and patient requirements early, we help reduce rework, control timelines, and de-risk progression into first-in-human and later-phase clinical studies.
 
Centrix is trusted by early-stage and virtual biotech companies seeking flexibility, transparency, and direct access to experienced scientists. With a focus on collaboration and scientific integrity, we don’t just deliver services. we help turn promising molecules into patient-ready medicines.
 
Molecule First. Patient Always.

Concept Life Sciences is a leading contract research organisation (CRO) serving the global life sciences industry. For over 25 years, the company, and its heritage companies, have provided consultative and collaborative drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables clients to overcome complex scientific challenges across a broad range of therapeutic areas, improving program success rates. The company has successfully helped 29 candidates advance to the clinic. 

The company offers sophisticated translational biology services coupled with exceptional end-to-end chemistry capabilities across all modalities including small molecules, biologics, peptides and cell & gene therapies, with the ability to seamlessly integrate capabilities and provide bespoke solutions to address client needs. 

Collectively, the company’s high-quality services and commitment to customer service across the drug development pathway enhances efficiency in drug discovery, helping clients advance their drugs to clinic in as little as 32 months, well ahead of the industry average of 60 months. 
Driven by a passion for science, Concept Life Sciences has around 230 employees, with around 70% holding PhDs. The company operates from state-of-the-art UK facilities, headquartered near Manchester, with additional operations in Edinburgh, Dundee, and Sandwich. The headquarters is one of the UK’s largest medicinal chemistry CRO sites with key discovery services all under one roof.  

Visit us at www.conceptlifesciences.com and follow us on LinkedIn.

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.  www.selcia.com 

• 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)  
• GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance  
• Stable Labelling  (13C, 2H, 15N) Internal Standards, Metabolites and Impurities  
• GLP Analysis Certification and Problem Solving including GLP NMR 

Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration 

Evestia Clinical is a global, mid‑size CRO dedicated to supporting life science innovators from Phase I to IV through a single‑partner model.  They provide a flexible, tailored suite of clinical trial services, from single service or FSP to full‑service, with primary focus in oncology, neurology, and rare diseases, and additional expertise in immunology and inflammation.

Anchored by a core presence in the US, UK, Europe, and Australia, Evestia Clinical delivers fast start‑up, pragmatic execution, and integrated study services, helping bring life‑changing therapies to patients sooner.

Evotec has been a leader in drug discovery and development for over 30 years, offering end-to-end solutions from target identification to clinical trials. Their innovative approach leverages deep disease understanding, cutting-edge technologies, and tailored solutions, supporting collaborations through standalone services, integrated programs, or strategic partnerships to create impactful medicines.

Our new tagline “Chemistry that delivers” captures the core of our offer: deep expertise in synthetic chemistry and scale-up, applied with rigour and purpose to deliver reliable outcomes. It speaks to our chemistry-first approach and our ability to support science-led organisations across pharmaceuticals, diagnostics, and advanced materials, not just in theory, but in practice.
Just as importantly, HFR remains a highly collaborative partner. Our director-led model and long-standing relationships mean you work directly with experienced chemists who understand your challenges and are invested in your success. That hands-on partnership continues to be central to how we operate.

HistologiX is a leading GLP/GCP compliant CRO supporting tissue based evaluation of your biomarkers; they help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Their experienced scientific team work as an extension of your in-house team and provide specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridisation (ISH) using RNAScope, digital pathology and image analysis services.

hVIVO plc (Ticker: HVO) is a science led drug development partner purpose-built to meet the growing complexity of modern clinical research. The Company operates an integrated end-to-end ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials. 

With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.

The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.

Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to current vector technology limiting efficacy, quality, and manufacturing viability. 

Lentitek has a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies and enable new applications such as in-vivo CAR-T and armoured CARs. Additionally, the improvement in manufacturing quality can lead to higher yields and improved product potency.